# Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients

> **NCT05688332** · PHASE3 · UNKNOWN · sponsor: **University of Zambia** · enrollment: 118 (estimated)

## Conditions studied

- Diabetes Mellitus Type 2 Without Complication

## Interventions

- **DRUG:** Voglibose + Metformin
- **DRUG:** Glibenclamide + Metformin

## Key facts

- **NCT ID:** NCT05688332
- **Lead sponsor:** University of Zambia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08
- **Primary completion:** 2023-12
- **Final completion:** 2024-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05688332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05688332, "Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05688332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*